ULURU Inc. Announces Poster Presentation on the Use of Altrazeal(TM) in Home Care
October 22 2009 - 7:30AM
PR Newswire (US)
- Indicates Ability to Generate Significant Cost Savings - Product
Promotes Patient Satisfaction with Treatment ADDISON, Texas, Oct.
22 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Alternext: ULU) today
announced that a poster highlighting the benefits of using
Altrazeal(TM) in the home care market segment will be among the
Altrazeal(TM) posters being presented at the 24th Annual "Clinical
Symposium on Advances in Skin and Wound Care" in San Antonio, Texas
from October 22-25. The poster, presented by Bobbie Spitz, R.N.,
M.S.N., CWS, from Aurora Home Health visiting nurse association of
Wisconsin, is entitled "Patient Selection for the Use of a Novel
Powder Dressing in Home Care." One important objective of home care
wound specialists is to find products that will decrease healing
time, nursing visits, pain of dressing changes and allow for
patients to be discharged with simple wound care procedures. The
purpose of this home care clinical evaluation was to develop and
test techniques to aid home care clinicians in selecting and
assessing patients with wounds that would benefit from treatment
with Altrazeal(TM). The clinical evaluation focused on: --
Describing criteria for selecting home care patients -- Describing
assessment criteria for determining wound progress -- Identifying
patient care and financial benefits of Altrazeal(TM) The poster
details the performance of Altrazeal(TM) in seven patients: -- Five
patients in their mid 80's to early 90's with lower extremity
trauma wounds which had, with prior treatment, healed to a small
dimension and then remained in stasis. These patients were
receiving 2-3 skilled nursing visits a week for wound care. In each
case through the use of Altrazeal(TM) the wound was resolved in 3-5
skilled nursing visits. Cost savings were demonstrated by a
reduction in the number of products used and nursing visits needed
for home care. Also, there was a high level of patient
satisfaction. -- An 18 year old with a pressure ulcer whose wound
had a slow healing progression after months of negative pressure
wound therapy. With Altrazeal(TM) being applied twice weekly the
wound decreased in dimension over 5 weeks. Skilled nursing visits
were reduced from 2-3 times weekly to once per week. -- An 89 year
old with a large surgical wound present for 3 years who was
receiving daily wound care treatment. After treatment with
Altrazeal(TM) there was a significant decrease in size of the
wound. Skilled nursing visits were decreased from three to one
weekly visit and there was a significant decrease in self care and
increase in patient satisfaction. Commenting on the results of this
clinical evaluation, Bobbie Spitz stated, "This product allows for
a cost efficient way to promote moist wound healing in home care
that also provides patient satisfaction. With the appropriate
selection of patients, Altrazeal(TM) can achieve the goals of
decreased healing time, reduced nursing visits and increasing
patient satisfaction." Altrazeal(TM), a transforming powder
dressing which is produced using our patented Nanoflex(TM)
Technology, is suitable for exuding wounds such as burns,
abrasions, trauma, skin graft donor sites, surgical wounds and
chronic slow-healing wounds such as diabetic foot ulcers, pressure
ulcers and venous ulcers. Altrazeal(TM) is an innovative
breakthrough, designed for greater effectiveness in wound closure
by promoting an optimal moist wound healing environment, reducing
pain and enhancing patient comfort, ease of application and removal
and, in most cases, not requiring a secondary dressing. Renaat Van
den Hooff, President and CEO of ULURU Inc. further commented,
"These are very important findings which confirm results achieved
in other wound care settings. This clinical evaluation is very
compelling and helps provide the necessary support to commence
expansion of sales activities in this important market segment."
The 24th Annual "Clinical Symposium on Advances in Skin and Wound
Care" will be held on October 22-25, 2009 at the Grand Hyatt San
Antonio and the Henry B. Gonzalez Convention Center in San Antonio,
Texas. For more information about the conference can be found at
http://www.symposiumonwoundcare.com/. About ULURU Inc.: ULURU Inc.
is a specialty pharmaceutical company focused on the development of
a portfolio of wound management and oral care products to provide
patients and consumers improved clinical outcomes through
controlled delivery utilizing its innovative Nanoflex(TM) Aggregate
technology and OraDisc(TM) transmucosal delivery system. For
further information about ULURU Inc., please visit our website at
http://www.uluruinc.com/. For further information about
Altrazeal(TM), please visit http://www.altrazeal.com/. This press
release contains certain statements that are forward-looking within
the meaning of Section 27a of the Securities Act of 1933, as
amended, including but not limited to statements made relating to
the benefits, effectiveness, success in wound healing, clinical
outcomes, and suitability of Altrazeal(TM), pharmacoeconomic
benefits and the success of our clinical efforts. These statements
are subject to numerous risks and uncertainties, including but not
limited to the risk factors detailed in the Company's Annual Report
on Form 10-K for the year ended December 31, 2008, and other
reports filed by us with the Securities and Exchange Commission.
Contact: Company Renaat E. Van den Hooff President & CEO Terry
K. Wallberg Vice President & CFO (214) 905-5145 DATASOURCE:
ULURU Inc. CONTACT: Renaat E. Van den Hooff President & CEO, or
Terry K. Wallberg, Vice President & CFO, both of ULURU Inc.,
+1-214-905-5145 Web Site: http://www.uluruinc.com/
http://www.altrazeal.com/ http://www.symposiumonwoundcare.com/
Copyright